DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DelveInsight's "DARZALEX Market Size, Forecast, and Market Insight Report" highlights the details around DARZALEX, a human ...
Hosted on MSN5mon
XtalPi’s AI biologics discovery platform licensed to Janssen Biotech
XtalPi, an AI drug discovery company and subsidiary of Ailux Biologics, has entered a licensing agreement with Janssen Biotech, a Johnson & Johnson company, to utilise its proprietary AI biologics ...
Biotech Alert: Searches spiking for these stocks today
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: ...
These 10 biotech companies are changing how we discover new drugs and treat complex diseases
The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...
pharmaphorum12y
Janssen, Phenex Pharma enter research collaboration worth up to $135 million
Janssen has entered into a collaboration agreement with Phenex Pharmaceuticals AG, a German drug discovery company that focuses on developing innovative small molecule therapeutics, in the fields ...
Nature2y
Janssen Oncology—leading the way in transformational innovation
Going deeper in MM science. Together with Legend Biotech, Janssen is developing a CAR-T cell therapy in MM. Janssen views this single asset collaboration as a foundational component of potential ...
DelveInsight Business Research, LLP: DARZALEX Continues to Redefine Multiple Myeloma Treatment with Robust Market Performance | DelveInsight
DARZALEX has significant market potential as a leading monoclonal antibody for multiple myeloma treatment. Its approval in various combinations for both newly diagnosed and relapsed/refractory ...